Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Acquisitions & Divestments: 2021-2024

Historic Change in Acquisitions & Divestments for 4D Molecular Therapeutics (FDMT) over the last 4 years, with Dec 2024 value amounting to $169.0 million.

  • 4D Molecular Therapeutics' Change in Acquisitions & Divestments fell 49.24% to $32.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $367.0 million, marking a year-over-year increase of 178.59%. This contributed to the annual value of $169.0 million for FY2024, which is 2.48% down from last year.
  • As of FY2024, 4D Molecular Therapeutics' Change in Acquisitions & Divestments stood at $169.0 million, which was down 2.48% from $173.3 million recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Change in Acquisitions & Divestments registered a high of $173.3 million during FY2023, and its lowest value of $5.0 million during FY2021.
  • Over the past 3 years, 4D Molecular Therapeutics' median Change in Acquisitions & Divestments value was $169.0 million (recorded in 2024), while the average stood at $163.4 million.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Change in Acquisitions & Divestments spiked by 2,855.98% in 2022 and then decreased by 2.48% in 2024.
  • Yearly analysis of 4 years shows 4D Molecular Therapeutics' Change in Acquisitions & Divestments stood at $5.0 million in 2021, then skyrocketed by 2,855.98% to $147.8 million in 2022, then climbed by 17.25% to $173.3 million in 2023, then dropped by 2.48% to $169.0 million in 2024.